Status:
TERMINATED
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
Lead Sponsor:
Pfizer
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor \[PPI\] tr...
Eligibility Criteria
Inclusion
- Subjects with a diagnosis of GERD who fulfill the following criteria:
- who have symptoms for least six months prior to enrollment; who are currently on daily treatment with a PPI and have been on such treatment for at least 3 months; whose symptoms are persistent, troublesome and that include heartburn and/or regurgitation as their predominant symptoms despite treatment with a PPI; who are seeking relief of persistent symptoms.
Exclusion
- Subjects with erosive esophagitis - An endoscopy within the last 5 years is required to verify absence.
- Subjects with any esophageal or gastric diseases/conditions that may contribute to their GERD symptoms.
- If female; pregnant, lactating or positive serum or urine pregnancy tests.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00730665
Start Date
January 1 2008
End Date
October 1 2008
Last Update
July 14 2011
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1200
2
Pfizer Investigational Site
Salvador, Estado de Bahia, Brazil, 40420-000
3
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil, 90035-003
4
Pfizer Investigational Site
Campinas, São Paulo, Brazil, 13070-040